


=> d l1  
 L1 HAS NO ANSWERS  
 L1 STR



VAR G1=O/S/N  
 VAR G2=1/5  
 VAR G3=32/35/38  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS. 41

STEREO ATTRIBUTES: NONE

=> s l1 ful  
 FULL SEARCH INITIATED 13:04:42 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 94468 TO ITERATE

100.0% PROCESSED 94468 ITERATIONS 96 ANSWERS  
 SEARCH TIME: 00.00.01

L3 96 SEA SSS FUL L1

=> fil caplus  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST  
 SINCE FILE ENTRY 171.34  
 TOTAL SESSION 171.97

FILE 'CAPLUS' ENTERED AT 13:04:47 ON 25 MAY 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2006 VOL 144 ISS 22  
FILE LAST UPDATED: 24 May 2006 (20060524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 17 L3

=> d bib 1-17

L4 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1144486 CAPLUS  
DN 144:51494  
TI Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists  
AU Xi, Ning; Bo, Yunxin; Doherty, Elizabeth M.; Fotsch, Christopher; Gavva, Narendra R.; Han, Nianhe; Hungate, Randall W.; Klionsky, Lana; Liu, Qingyian; Tamir, Rami; Xu, Shimin; Treanor, James J. S.; Norman, Mark H.  
CS Chemistry Research and Discovery, Amgen Inc., Thousand Oaks, CA, 91320, USA  
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(23), 5211-5217  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier B.V.  
DT Journal  
LA English  
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1026876 CAPLUS  
DN 143:326362  
TI Preparation of substituted imidazoles as calcium ion channel modulators  
IN Zelle, Robert; Galullo, Vincent P.; Baker, Christopher Todd; Will, Paul; Frazee, William J.; Mazdiyasni, Hormoz; Guo, Jinsong  
PA Scion Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 430 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2005086836	A2	20050922	WO 2005-US7667	20050307
	WO 2005086836	A3	20060105		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,				

SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG

PRAI US 2004-551372P P 20040308  
US 2004-551395P P 20040308  
US 2004-551472P P 20040308  
US 2004-551473P P 20040308  
US 2004-551474P P 20040308  
US 2004-551480P P 20040308  
US 2004-551503P P 20040308  
US 2004-551510P P 20040308  
US 2004-551620P P 20040308

OS MARPAT 143:326362

L4 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:471944 CAPLUS

DN 143:26594

TI Preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette (ABC) transporters

IN Hadida Ruah, Sarah S.; Miller, Mark T.; Grootenhuys, Peter D. J.;  
Hamilton, Matthew

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049018	A1	20050602	WO 2004-US38566	20041115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2005130970 A1 20050616 US 2004-989218 20041115

PRAI US 2003-520355P P 20031114

OS MARPAT 143:26594

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:470256 CAPLUS

DN 143:20052

TI Urea derivatives as kinase modulators

IN Milanov, Zdravko V.; Patel, Hitesh K.; Grotzfeld, Robert M.; Mehta, Shamal A.; Andiliy, Lai G.; Lockhart, David J.

PA Ambit Biosciences Corporation, USA

SO PCT Int. Appl., 350 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2005048948 A2 20050602 WO 2004-US38288 20041115  
 WO 2005048948 A3 20050728  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,  
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG  
 US 2005148605 A1 20050707 US 2004-989745 20041115  
 US 2005165031 A1 20050728 US 2004-989814 20041115  
 US 2005165024 A1 20050728 US 2004-989824 20041115  
 US 2005165074 A1 20050728 US 2004-990007 20041115  
 US 2005171171 A1 20050804 US 2004-989766 20041115  
 US 2005171172 A1 20050804 US 2004-989823 20041115  
 US 2005192314 A1 20050901 US 2004-990195 20041115  
 US 2005197371 A1 20050908 US 2004-990194 20041115  
 US 2005261315 A1 20051124 US 2004-989623 20041115  
 US 2005267182 A1 20051201 US 2004-989717 20041115  
 PRAI US 2003-520273P P 20031113  
 US 2003-527094P P 20031203  
 US 2003-531082P P 20031218  
 US 2003-531243P P 20031218  
 OS MARPAT 143:20052

L4 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:696342 CAPLUS  
 DN 141:225302  
 TI Preparation of N-arylheterocycles as melanin concentrating hormone (MCH)  
 antagonists.  
 IN Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme, Thomas;  
 Hessler, Gerhard; Stahl, Petra; Gretzke, Dirk  
 PA Aventis Pharma Deutschland GmbH, Germany  
 SO PCT Int. Appl., 390 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004072025	A2	20040826	WO 2004-EP1342	20040213
	WO 2004072025	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10306250	A1	20040909	DE 2003-10306250	20030214
	AU 2004212145	A1	20040826	AU 2004-212145	20040213
	CA 2516118	AA	20040826	CA 2004-2516118	20040213
	EP 1597228	A2	20051123	EP 2004-710808	20040213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004007504	A	20060214	BR 2004-7504	20040213
	US 2004220191	A1	20041104	US 2004-779853	20040217
	NO 2005004220	A	20051028	NO 2005-4220	20050912
PRAI	DE 2003-10306250	A	20030214		

US 2003-488545P P 20030718  
WO 2004-EP1342 A 20040213  
OS MARPAT 141:225302

L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:654774 CAPLUS  
DN 141:190788  
TI A preparation of N-containing heterocyclic compounds, useful as vanilloid  
receptor ligands  
IN Doherty, Elizabeth M.; Fotsch, Christopher H.; Han, Nianhe; Hungate,  
Randall W.; Liu, Qingyian; Norman, Mark H.; Xi, Ning; Xu, Shimin  
PA Amgen Inc., USA  
SO U.S. Pat. Appl. Publ., 38 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004157845	A1	20040812	US 2004-775980	20040209
	AU 2004212490	A1	20040826	AU 2004-212490	20040209
	CA 2515215	AA	20040826	CA 2004-2515215	20040209
	WO 2004072068	A1	20040826	WO 2004-US3908	20040209
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1603905	A1	20051214	EP 2004-709532	20040209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2003-446511P	P	20030210		
	WO 2004-US3908	W	20040209		
OS	MARPAT 141:190788				

L4 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:279454 CAPLUS  
DN 134:295831  
TI Preparation of 2-(2-alkoxy-5-heterocyclylsulfonylphenyl)purin-6-ones as  
phosphodiesterase inhibitors  
IN Maw, Graham Nigel; Rawson, David James  
PA Pfizer Limited, UK; Pfizer Inc.  
SO Eur. Pat. Appl., 44 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1092718	A1	20010418	EP 2000-308644	20001002
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6440982	B1	20020827	US 2000-650848	20000829
	CA 2322900	AA	20010411	CA 2000-2322900	20001006
	CA 2322900	C	20050208		
	JP 2001114782	A2	20010424	JP 2000-310665	20001011
	JP 3727525	B2	20051214		
	BR 2000004786	A	20010522	BR 2000-4786	20001011
	JP 2003128673	A2	20030508	JP 2002-224638	20001011
	US 2003004173	A1	20030102	US 2002-189655	20020703
	US 6593332	B2	20030715		

US 2003013727	A1	20030116	US 2002-189680	20020703
US 6586439	B2	20030701		
PRAI GB 1999-24020	A	19991011		
US 2000-650848	A3	20000829		
JP 2000-310665	A3	20001011		

OS MARPAT 134:295831

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2000:98304 CAPLUS  
DN 132:151564  
TI Preparation of substituted anilides as modulators, agonists or antagonists of the CCR5 receptor  
IN Ku, Thomas W.; Bondinell, William E.; Neeb, Michael J.  
PA Smithkline Beecham Corporation, USA  
SO PCT Int. Appl., 51 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006146	A1	20000210	WO 1999-US17121	19990728
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2338764	AA	20000210	CA 1999-2338764	19990728
	AU 9952392	A1	20000221	AU 1999-52392	19990728
	BR 9912406	A	20010424	BR 1999-12406	19990728
	EP 1100485	A1	20010523	EP 1999-937589	19990728
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200100267	T2	20010921	TR 2001-200100267	19990728
	JP 2002521436	T2	20020716	JP 2000-562001	19990728
	NO 2001000446	A	20010126	NO 2001-446	20010126
PRAI	US 1998-94406P	P	19980728		
	US 1999-134157P	P	19990514		
	WO 1999-US17121	W	19990728		

OS MARPAT 132:151564

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1999:495272 CAPLUS  
DN 131:130011  
TI Preparation of N-acyl-2-aminoacetamides and cyclization products thereof.  
IN Hulme, Christopher; Morton, George C.; Salvino, Joseph M.; Labaudiniere, Richard F.; Mason, Helen J.; Morrisette, Matthew M.; Ma, Liang; Cherrier, Marie-Pierre  
PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA  
SO PCT Int. Appl., 156 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938844	A1	19990805	WO 1999-US1923	19990129
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK,				

EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,  
 VN, YU, ZW  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2318601 AA 19990805 CA 1999-2318601 19990129  
 AU 9924821 A1 19990816 AU 1999-24821 19990129  
 AU 747987 B2 20020530  
 ZA 9900729 A 20000110 ZA 1999-729 19990129  
 EP 1051397 A1 20001115 EP 1999-904421 19990129  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO  
 BR 9908207 A 20001128 BR 1999-8207 19990129  
 JP 2002501944 T2 20020122 JP 2000-530081 19990129  
 AP 1462 A 20050930 AP 2000-200001864 19990129  
 W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW  
 US 6492553 B1 20021210 US 1999-368213 19990804  
 NO 2000003792 A 20000927 NO 2000-3792 20000724  
 BG 104724 A 20010330 BG 2000-104724 20000829  
 PRAI US 1998-73007P A2 19980129  
 US 1998-98404P A2 19980831  
 US 1998-98708P A2 19980901  
 US 1998-101056P A2 19980918  
 WO 1999-US1923 W 19990129  
 OS MARPAT 131:130011  
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1998:816534 CAPLUS  
 DN 130:110257  
 TI Preparation of thiazole derivatives and their pharmaceutical uses  
 IN Sugihara, Yoshihiro; Uchibayashi, Naoto; Maezaki, Hironobu; Nozaki,  
 Yukimasa; Ichimori, Yuzo; Ii, Masayuki  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 29 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10338680	A2	19981222	JP 1997-149739	19970606
JP 1997-149739		19970606		

  
 OS MARPAT 130:110257

L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1994:323346 CAPLUS  
 DN 120:323346  
 TI Ring chain transformations. XII. Synthesis of N-(3-  
 aminothioacryloyl)lactam imines and their transformation to  
 4-(ω-amino-alkyl)thiazoles or N-(thien-2-yl)lactam imines  
 AU Paetzel, Michael; Knoll, Alexander; Steinke, Thomas; von Loewis, Michael;  
 Liebscher, Juergen  
 CS Fachbereich Chem., Humboldt-Univ., Berlin, Germany  
 SO Journal fuer Praktische Chemie/Chemiker-Zeitung (1993), 335(7), 639-43  
 CODEN: JPCCEM; ISSN: 0941-1216  
 DT Journal  
 LA English

L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1989:135271 CAPLUS

DN 110:135271  
 TI Preparation of imidazothiadiazines as hypotensives and vasodilators  
 IN Ohsaki, Tsutomu; Sakakibara, Jinsaku; Kuriki, Takeo  
 PA Hoechst Japan Ltd., Japan  
 SO Eur. Pat. Appl., 19 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 286041	A1	19881012	EP 1988-105347	19880402
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 01025786	A2	19890127	JP 1987-209066	19870821
	JP 2552494	B2	19961113		
	US 4942143	A	19900717	US 1988-178231	19880406
	DK 8801894	A	19881009	DK 1988-1894	19880407
PRAI	JP 1987-86130	A	19870408		
	JP 1987-209066	A	19870821		
OS	CASREACT 110:135271; MARPAT 110:135271				

L4 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1989:38935 CAPLUS  
 DN 110:38935  
 TI Reactions of mesoionic five-membered heterocycles with o-quinoid compounds. VII. Thermal [ $\pi 4 + \pi 4$ ]cycloadditions of a bicyclic imidazolo[1,2-c]thiazole system  
 AU Friedrichsen, Willy; Koenig, B. Michael; Debaerdemaeker, Tony  
 CS Inst. Org. Chem., Univ. Kiel, Kiel, D-2300, Fed. Rep. Ger.  
 SO Zeitschrift fuer Naturforschung, B: Chemical Sciences (1988), 43(3), 347-60  
 CODEN: ZNBSEN; ISSN: 0932-0776  
 DT Journal  
 LA German  
 OS CASREACT 110:38935

L4 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1983:405563 CAPLUS  
 DN 99:5563  
 TI Nitroimidazoles: Part XVII. 5-Aminoimidazoles  
 AU Sudarsanam, V.; Nagarajan, K.; Gokhale, N. G.  
 CS Ciba-Geigy Res. Cent., Bombay, 400 063, India  
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1982), 21B(12), 1087-91  
 CODEN: IJSBDB; ISSN: 0376-4699  
 DT Journal  
 LA English  
 OS CASREACT 99:5563

L4 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1974:515750 CAPLUS  
 DN 81:115750  
 TI Systemic and chemotherapeutic fungicidal activity-chemical structure relation of some 4-methyl-5-thiazolecarboxylic acid derivatives. Laboratory screening tests  
 AU Abdel-Lateef, Mahmoud F. A.; Stec, Maria; Eckstein, Zygmunt  
 CS Fac. Agric., Al-Azhar Univ., Cairo, Egypt  
 SO Acta Phytopathologica Academiae Scientiarum Hungaricae (1973), 8(3-4), 269-82  
 CODEN: APYPBZ; ISSN: 0001-6780  
 DT Journal  
 LA English

L4 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN



AN 1973:147941 CAPLUS  
 DN 78:147941  
 TI Thiazole-5-carboxanilide hydrochlorides  
 IN Girgis, Mikhail Milad  
 PA Uniroyal Ltd.  
 SO Ger. Offen., 18 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	----	-----	-----
PI	DE 2242471	A1	19730308	DE 1972-2242471	19720829
	US 3794636	A	19740226	US 1971-177822	19710903
	CA 970779	A1	19750708	CA 1972-148093	19720727
	GB 1401680	A	19750730	GB 1972-40027	19720829
	FR 2152056	A5	19730420	FR 1972-31134	19720901
	NL 7211992	A	19730306	NL 1972-11992	19720902
	IT 968312	A	19740320	IT 1972-69805	19720902
	JP 48039477	A2	19730609	JP 1972-88608	19720904
PRAI	US 1971-177822	A	19710903		

L4 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1963:53202 CAPLUS

DN 58:53202

OREF 58:9040e-h

TI Compounds with potential antitubercular activity. IV. N-Substituted thioamides of 4-Oxazolecarboxylic acids

AU Sycheva, T. P.; Trupp, T. Kh.; Shchukina, M. N.

CS S. Ordzhonikidze All-Union Chem.-Pharm. Research Inst., Moscow


SO Zhurnal Obshchei Khimii (1962), 32, 2882-5

CODEN: ZOKHA4; ISSN: 0044-460X


DT Journal

LA Unavailable

AN 1963:53202 CAPLUS  
 DN 58:53202  
 OREF 58:9040e-h  
 TI Compounds with potential antitubercular activity. IV. N-Substituted thioamides of 4-Oxazolecarboxylic acids  
 AU Sycheva, T. P.; Trupp, T. Kh.; Shchukina, M. N.  
 CS S. Ordzhonikidze All-Union Chem.-Pharm. Research Inst., Moscow  
 SO Zhurnal Obshchei Khimii (1962), 32, 2882-5  
 CODEN: ZOKHA4; ISSN: 0044-460X  
 DT Journal  
 LA Unavailable  
 GI For diagram(s), see printed CA Issue.  
 AB cf. CA 58, 1448h. Addition of 6.9 g. POCl<sub>3</sub> to 3.81 g. 2-methyl-4-oxazolecarboxylic acid and 2.79 g. PhNH<sub>2</sub> and heating 1 hr. at 130° gave after an aqueous treatment 8.9 g. 2-methyl-4-oxazolecarboxanilide (I, R = Me) (II), m. 133.5-5.5°. Similarly were prepared the following I (R given): PhCH<sub>2</sub>, m. 109.5-11°; Ph, m. 187-9°; p-MeC<sub>6</sub>H<sub>4</sub>, m. 180.5-2.5°. Similarly were prepared: 2-benzyl-4-oxazolecarbomoypholide, m. 108-10° and the corresponding p-toluidide, m. 121-2°. II (1 g.) in 25 ml. pyridine heated with 2 g. P<sub>2</sub>S<sub>5</sub> at 120-30° (bath temperature) 4 hrs. gave after an aqueous treatment and extraction of the precipitate with hot MeOH, 0.25 g. yellow 2-methyl-4-oxazolecarbothioanilide (III), m. 123-5°. Similarly were prepared the III analogs with following 2-substituents: PhCH<sub>2</sub>, m. 111-13.5; Ph, m. 104-5°. Similarly were prepared 2-benzyl-4-oxazolecarbothio-p-toluidide, m. 91-3°, and the analogous thiomorpholide, m. 94-6°. 2-p-Tolyl-4-oxazolecarboxanilide and P<sub>2</sub>S<sub>5</sub> in pyridine 10 hrs. at 120-30° gave after an aqueous treatment yellow 2-p-tolyl-4-thiazolecarbothioanilide, m. 147-9°. Et 2-p-tolyl-4-oxazolecarboxylate in 2N NaOH 1 hr. gave the free acid, decomposed 229-30°. The replacement of the hetero O atom by S in the reaction with P<sub>2</sub>S<sub>5</sub> was not observed for the other examples above.  
 IT 93323-65-0, 4-Oxazolecarboxanilide, 2-benzyl- 98511-88-7, 4-Oxazolecarboxy-p-toluidide, 2-benzyl- (preparation of)  
 RN 93323-65-0 CAPLUS  
 CN 4-Oxazolecarboxanilide, 2-benzyl- (7CI) (CA INDEX NAME)



RN 98511-88-7 CAPLUS  
 CN 4-Oxazolecarboxy-p-toluidide, 2-benzyl- (7CI) (CA INDEX NAME)



=> s l4 and vanilloid  
1459 VANILLOID  
L5 2 L4 AND VANILLOID

=> d bib 1-2

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1144486 CAPLUS  
DN 144:51494  
TI Synthesis and evaluation of thiazole carboxamides as **vanilloid**  
receptor 1 (TRPV1) antagonists  
AU Xi, Ning; Bo, Yunxin; Doherty, Elizabeth M.; Fotsch, Christopher; Gavva,  
Narender R.; Han, Nianhe; Hungate, Randall W.; Klionsky, Lana; Liu,  
Qingyian; Tamir, Rami; Xu, Shimin; Treanor, James J. S.; Norman, Mark H.  
CS Chemistry Research and Discovery, Amgen Inc., Thousand Oaks, CA, 91320,  
USA  
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(23), 5211-5217  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier B.V.  
DT Journal  
LA English  
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:654774 CAPLUS  
DN 141:190788  
TI A preparation of N-containing heterocyclic compounds, useful as  
**vanilloid** receptor ligands  
IN Doherty, Elizabeth M.; Fotsch, Christopher H.; Han, Nianhe; Hungate,  
Randall W.; Liu, Qingyian; Norman, Mark H.; Xi, Ning; Xu, Shimin  
PA Amgen Inc., USA  
SO U.S. Pat. Appl. Publ., 38 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004157845	A1	20040812	US 2004-775980	20040209
	AU 2004212490	A1	20040826	AU 2004-212490	20040209
	CA 2515215	AA	20040826	CA 2004-2515215	20040209
	WO 2004072068	A1	20040826	WO 2004-US3908	20040209
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1603905	A1	20051214	EP 2004-709532	20040209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2003-446511P	P	20030210		
	WO 2004-US3908	W	20040209		
OS	MARPAT 141:190788				

=> s l4 not l5  
L6 15 L4 NOT L5

4

4

4




AB The title imidazoles such as I [Ar1 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl; X = NR3, C(R3)2, O; Y = C(O), alkylene; R1 = Ar2, alkyl optionally substituted with Ar2 (wherein Ar2 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl); q = 0-2; R2 = (CH2)mCO2R3, (CH2)mC(O)Ar3, (CH2)mAr3, etc. (R3 = H, alkyl; m = 1-2; Ar3 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl)] which can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets, were prepared E.g., a multi-step synthesis of II, starting from p-toluidine, was given. Oocyte assays, HEK assays, and formalin tests were carried out (no data given).

IT 865079-41-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of substituted imidazoles as calcium ion channel modulators)

RN 865079-41-0 CAPLUS

CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-N-(4-fluorophenyl)-2-[(4-fluorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:471944 CAPLUS

DN 143:26594

TI Preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette (ABC) transporters

IN Hadida Ruah, Sarah S.; Miller, Mark T.; Grootenhuis, Peter D. J.; Hamilton, Matthew

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 146 pp.  
 CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049018	A1	20050602	WO 2004-US38566	20041115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005130970	A1	20050616	US 2004-989218	20041115

PRAI US 2003-520355P P 20031114  
OS MARPAT 143:26594  
GI




AB A method of modulating ABC transporter activity comprises administration of title compds. [I; X = O, S; R1 = H, 3-8 membered (substituted) (unsatd.) (heterocyclic) ring; Z = bond, (substituted) (heteroatom-interrupted) alkylidene; R2 = halo, CF3, cyano, NO2, TqR; R3 = UmR'; R4 = VpCyl; m, p, q = 0, 1; U, V, T = (substituted) (heteroatom-interrupted) alkylidene; Cyl = 3-8 membered (substituted) (unsatd.) (heterocyclic) ring; R = H, (substituted) aliphatic; R' = R, (substituted) (unsatd.) (heterocyclic) ring]. Thus, 2-(4-methoxybenzyl)thiazole-4-carboxylic acid, C-[1-(3,4-dimethoxyphenyl)cyclopentyl]methylamine (preparation given), Et3N, and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate were stirred together for 16 h in MeCN to give 43.9% 2-(4-methoxybenzyl)thiazole-4-carboxylic acid [1-(3,4-dimethoxyphenyl)cyclopentyl]methylamide. Some I exhibit a relative modulating efficacy of >30%.

IT 852639-06-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters)

RN 852639-06-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-[(2,6-dichlorophenyl)methyl]-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:470256 CAPLUS

DN 143:20052

TI Urea derivatives as kinase modulators

IN Milanov, Zdravko V.; Patel, Hitesh K.; Grotzfeld, Robert M.; Mehta, Shamal A.; Andiliy, Lai G.; Lockhart, David J.

PA Ambit Biosciences Corporation, USA


SO PCT Int. Appl., 350 pp.

CODEN: PIXXD2

DT Patent

LA English  
FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005048948	A2	20050602	WO 2004-US38288	20041115
	WO 2005048948	A3	20050728		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005148605	A1	20050707	US 2004-989745	20041115
	US 2005165031	A1	20050728	US 2004-989814	20041115
	US 2005165024	A1	20050728	US 2004-989824	20041115
	US 2005165074	A1	20050728	US 2004-990007	20041115
	US 2005171171	A1	20050804	US 2004-989766	20041115
	US 2005171172	A1	20050804	US 2004-989823	20041115
	US 2005192314	A1	20050901	US 2004-990195	20041115
	US 2005197371	A1	20050908	US 2004-990194	20041115
	US 2005261315	A1	20051124	US 2004-989623	20041115
	US 2005267182	A1	20051201	US 2004-989717	20041115
PRAI	US 2003-520273P	P	20031113		
	US 2003-527094P	P	20031203		
	US 2003-531082P	P	20031218		
	US 2003-531243P	P	20031218		
OS	MARPAT 143:20052				
AB	The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of urea compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects such as cellular proliferative disorders.				
IT	852671-22-8				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (urea derivs. as kinase modulators for treatment of cellular proliferative disorders)				
RN	852671-22-8	CAPLUS			
CN	4-Thiazolecarboxamide, N-[4-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]-2-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)				



L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:696342 CAPLUS  
DN 141:225302  
TI Preparation of N-arylheterocycles as melanin concentrating hormone (MCH) antagonists.

IN Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme, Thomas;  
Hessler, Gerhard; Stahl, Petra; Gretzke, Dirk  
PA Aventis Pharma Deutschland GmbH, Germany  
SO PCT Int. Appl., 390 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004072025	A2	20040826	WO 2004-EP1342	20040213
	WO 2004072025	A3	20041223		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10306250	A1	20040909	DE 2003-10306250	20030214
	AU 2004212145	A1	20040826	AU 2004-212145	20040213
	CA 2516118	AA	20040826	CA 2004-2516118	20040213
	EP 1597228	A2	20051123	EP 2004-710808	20040213
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2004007504	A	20060214	BR 2004-7504	20040213
	US 2004220191	A1	20041104	US 2004-779853	20040217
	NO 2005004220	A	20051028	NO 2005-4220	20050912
PRAI	DE 2003-10306250	A	20030214		
	US 2003-488545P	P	20030718		
	WO 2004-EP1342	A	20040213		
OS	MARPAT 141:225302				
GI					



I

AB Title compds. [I; R1, R2 = H, alkyl, alkoxyalkyl, aryloxyalkyl, alkylcarbonyl, alkenylcarbonyl, etc.; R1R2N = atoms to form a 4-10 membered mono-, bi-, or spirocyclic (substituted) ring; R3 = H, alkyl; R4, R5 = H, alkyl, OH, alkoxy, alkylcarbonyloxy, alkylthio; R6-R9 = H, alkyl; R6R7, R8R9 = O; A, B, D, G = N, CR42; AB, DG = CR42; R42 = H, F, Cl, Br, iodo, CF3, NO2, cyano, OCF3, alkoxy, alkylthio, alkenyl, cycloalkyl, cycloalkoxy, cycloalkenyl, alkynyl, CO2H, etc.; R10 = H, alkyl, alkenyl, alkynyl; X = NR52, O, bond, C:C, C.tplbond.C, etc.; R52 = H, alkyl; E = (substituted) C3-14 carbocyclyl, heterocyclyl; K = bond, O, CH2O, S, SO, CO, C:C, C.tplbond.C, etc.; R11 = H, alkyl, alkoxyalkyl, alkenyl, alkynyl, 3-10 membered (substituted) mono-, bi-, tri- or spirocyclic ring; EKR11 = (unsatd.) tricyclic ring; m, n = 0-2], were prepared Thus, N-[1-(4-aminophenyl)pyrrolidin-3-yl]piperidine was treated with carbonyldiimidazole and then with 4-(4-chlorophenyl)piperidine to give 4-(4-chlorophenyl)piperidine-1-carboxylic acid [4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl]amide. The latter at 30 mg/kg



orally in female NMRI mice reduced milk consumption by 64%.


IT 748175-48-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-arylheterocycles as MCH antagonists)

RN 748175-48-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-2-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:279454 CAPLUS

DN 134:295831

TI Preparation of 2-(2-alkoxy-5-heterocyclylsulfonylphenyl)purin-6-ones as phosphodiesterase inhibitors

IN Maw, Graham Nigel; Rawson, David James

PA Pfizer Limited, UK; Pfizer Inc.

SO Eur. Pat. Appl., 44 pp.


CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1092718	A1	20010418	EP 2000-308644	20001002
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6440982	B1	20020827	US 2000-650848	20000829
	CA 2322900	AA	20010411	CA 2000-2322900	20001006
	CA 2322900	C	20050208		
	JP 2001114782	A2	20010424	JP 2000-310665	20001011
	JP 3727525	B2	20051214		
	BR 2000004786	A	20010522	BR 2000-4786	20001011
	JP 2003128673	A2	20030508	JP 2002-224638	20001011
	US 2003004173	A1	20030102	US 2002-189655	20020703
	US 6593332	B2	20030715		
	US 2003013727	A1	20030116	US 2002-189680	20020703
	US 6586439	B2	20030701		
PRAI	GB 1999-24020	A	19991011		
	US 2000-650848	A3	20000829		
	JP 2000-310665	A3	20001011		
OS	MARPAT 134:295831				
GI					



I



II

AB The title compds. [I or II; X = CH, N; R1 = H, CN, aryl, etc.; R2 = H, aryl, alkyl, etc.; R3 = H, (un)substituted alkyl; Het1 = 4-12 membered heterocyclyl which contains at least one N atom and, optionally, one or more further heteroatoms selected from N, O, and/or S], useful in the curative and prophylactic treatment of medical conditions for which inhibition of a cyclic guanosine 3',5'-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired (such as male erectile dysfunction), were prepared and formulated. E.g., 3-step synthesis of II [X = CH; R1 = H; R2, R3 = Pr; Het1 = 4-(pyridin-2-yl)piperazin-1-yl] which showed 100% PDE5 inhibition at 10 nM, was given.


IT 334497-15-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-(2-alkoxy-5-heterocyclylsulfonylphenyl)purin-6-ones as phosphodiesterase inhibitors)

RN 334497-15-3 CAPLUS

CN 1H-Imidazole-4-carboxamide, 5-[(2-ethoxybenzoyl)amino]-2-(phenylmethyl)-1-propyl- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:98304 CAPLUS

DN 132:151564

TI Preparation of substituted anilides as modulators, agonists or antagonists of the CCR5 receptor

IN Ku, Thomas W.; Bondinell, William E.; Neeb, Michael J.

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006146	A1	20000210	WO 1999-US17121	19990728
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU,				

ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX,  
 NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG



CA 2338764	AA	20000210	CA 1999-2338764	19990728
AU 9952392	A1	20000221	AU 1999-52392	19990728
BR 9912406	A	20010424	BR 1999-12406	19990728
EP 1100485	A1	20010523	EP 1999-937589	19990728

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

TR 200100267	T2	20010921	TR 2001-200100267	19990728
JP 2002521436	T2	20020716	JP 2000-562001	19990728
NO 2001000446	A	20010126	NO 2001-446	20010126

PRAI US 1998-94406P	P	19980728
US 1999-134157P	P	19990514
WO 1999-US17121	W	19990728

OS MARPAT 132:151564  
 GI




AB The title compds. [I; the basic N in moiety E may be optionally quaternized with alkyl or is optionally present as the N-oxide; P1, P2 = Ph, fused bicyclic aryl, monocyclic heterocyclyl, etc.; A = CO, O, SOc, etc.; L = CH2NH, NHCH2, etc.; R1, R2 = H, alkyl, alkenyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; a, b = 1-3; c = 0-2] which are modulators, agonists or antagonists of the CCR5 receptor, and therefore useful in treating COPD, asthma and atopic disorders, rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, and HIV, were prepared E.g., a synthesis of benzamide II starting with (4-formyl-3,5-dimethoxyphenoxy)-Merrifield resin and 3-[2-(diethylamino)ethoxy]-4-methoxyaniline, was given. Compds. I show CCR5 receptor modulator activity having IC50 values of 0.0001 to 100  $\mu$ M.

IT 257616-35-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted anilides as modulators, agonists or antagonists of the CCR5 receptor)

RN 257616-35-6 CAPLUS  
 CN 4-Thiazolecarboxamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:495272 CAPLUS  
 DN 131:130011  
 TI Preparation of N-acyl-2-aminoacetamides and cyclization products thereof.  
 IN Hulme, Christopher; Morton, George C.; Salvino, Joseph M.; Labaudiniere, Richard F.; Mason, Helen J.; Morrisette, Matthew M.; Ma, Liang; Cherrier, Marie-Pierre  
 PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA  
 SO PCT Int. Appl., 156 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938844	A1	19990805	WO 1999-US1923	19990129
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2318601	AA	19990805	CA 1999-2318601	19990129
AU 9924821	A1	19990816	AU 1999-24821	19990129
AU 747987	B2	20020530		
ZA 9900729	A	20000110	ZA 1999-729	19990129
EP 1051397	A1	20001115	EP 1999-904421	19990129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9908207	A	20001128	BR 1999-8207	19990129
JP 2002501944	T2	20020122	JP 2000-530081	19990129
AP 1462	A	20050930	AP 2000-200001864	19990129
W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
US 6492553	B1	20021210	US 1999-368213	19990804
NO 2000003792	A	20000927	NO 2000-3792	20000724
BG 104724	A	20010330	BG 2000-104724	20000829
PRAI US 1998-73007P	A2	19980129		
US 1998-98404P	A2	19980831		
US 1998-98708P	A2	19980901		
US 1998-101056P	A2	19980918		
WO 1999-US1923	W	19990129		

OS MARPAT 131:130011  
 AB RaRbNCRcaRcbRd Ra = RaaCO; Dd = CONHRda; Raa, Rb, Rca, Rcb = H, (substituted) alipharyl, aryl; Rda = (substituted) alipharyl, aryl; with provisos were prepared by reaction of RcaCORcb with RbNH<sub>2</sub>, RaCO<sub>2</sub>H, and NCRda. Title compds. may be prepared on a isocyanide resin and deprotected/cyclized to give 1,4-benzodiazepine-2,5-diones, diketopiperazines, ketopiperazines, lactams, 1,4-benzodiazapines, and dihydroquinoxalinones.  
 IT 234781-43-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of N-acyl-2-aminoacetamides and cyclization products thereof)  
 RN 234781-43-2 CAPLUS  
 CN 1H-Imidazole-5-carboxamide, 2-(diphenylmethyl)-4,5-dihydro-N-phenyl-4-[[4-(phenylmethoxy)phenyl]methyl]-1-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1998:816534 CAPLUS  
 DN 130:110257  
 TI Preparation of thiazole derivatives and their pharmaceutical uses  
 IN Sugihara, Yoshihiro; Uchibayashi, Naoto; Maezaki, Hironobu; Nozaki, Yukimasa; Ichimori, Yuzo; Ii, Masayuki  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 29 pp.  
 CODEN: JKXXAF

DT Patent  
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10338680	A2	19981222	JP 1997-149739	19970606
PRAI	JP 1997-149739		19970606		
OS	MARPAT 130:110257				
GI					



AB The derivs. I [R1 = (un)substituted hydrocarbyl, (un)substituted heterocyclyl, (un)substituted amino; n = 1, 2; R2 = cyano, (un)substituted acyl, (un)substituted (thio)carbamoyl, (un)esterified carboxy, (un)substituted vinyl, (un)substituted ethynyl, (un)substituted amidino, (un)substituted halomethyl; R3 = group linked via C; if R2 = CO<sub>2</sub>Et, then R1 = (un)substituted hydrocarbyl, (un)substituted heterocyclyl] or their salts are prepared NO formation inhibitors and interleukin 6 inhibitors containing I or their salts are also claimed. I and their salts are useful

for prevention and treatment of heart diseases, autoimmune diseases, inflammatory diseases, and granulomatous diseases, etc. A toluene solution of 3,3-bis(methylthio)-2-N-triphenylphosphoranylideneaminoacrylonitrile (preparation given) was treated with BzCl under reflux for 4 h and the resulting product was oxidized with m-ClC<sub>6</sub>H<sub>4</sub>CO<sub>3</sub>H at room temperature for 1 h to give 2-phenyl-5-methylsulfonyl-4-thiazolecarbonitrile. This inhibited interferon  $\gamma$ -induced NO formation by RAW264.7 cell at IC<sub>50</sub> 0.023  $\mu$ M.


IT 219623-66-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiazole derivs. as NO synthesis inhibitors and IL-6 inhibitors, and their pharmaceutical uses)

RN 219623-66-2 CAPLUS

CN 4-Thiazolecarboxamide, N-ethyl-5-methyl-N-phenyl-2-(phenylmethyl)- (9CI)  
(CA INDEX NAME)



L6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:323346 CAPLUS

DN 120:323346

TI Ring chain transformations. XII. Synthesis of N-(3-aminothioacryloyl)lactam imines and their transformation to 4-( $\omega$ -amino-alkyl)thiazoles or N-(thien-2-yl)lactam imines

AU Paetzel, Michael; Knoll, Alexander; Steinke, Thomas; von Loewis, Michael; Liebscher, Juergen

CS Fachbereich Chem., Humboldt-Univ., Berlin, Germany


SO Journal fuer Praktische Chemie/Chemiker-Zeitung (1993), 335(7), 639-43

CODEN: JPCCEM; ISSN: 0941-1216


DT Journal

LA English


GI




I



II



III



IV


AB 3-Aminothioacrylamides R2NCH:CR1CSNH2 (R2N = piperidino, pyrrolidino, morpholino Me2N; R1 = Ph, 4-ClC6H4, cyano) reacts with lactam acetals I (n = 1, 2, 3) to give the (aminothioacryloyl)lactam imines II. II reacted with R2CH2X (R2 = 4-bromobenzoyl, NO2, 5-nitro-2-furyl, etc.; X = halo) to give the N-(thien-2-yl)lactam imines III and 4-(ω-amino-alkyl)thiazoles IV. The MNDO calcns. of semicyclic aza(chlorobenzyl)pentamethinium intermediates was discussed.

IT 155243-66-6P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 155243-66-6 CAPLUS

CN 4-Thiazolepentanamine, 5-(1H-benzimidazol-2-yl)-2-[1-(4-chlorophenyl)-2-(1-piperidinyl)ethenyl]-N-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1989:135271 CAPLUS  
DN 110:135271  
TI Preparation of imidazothiadiazines as hypotensives and vasodilators  
IN Ohsaki, Tsutomu; Sakakibara, Jinsaku; Kuriki, Takeo  
PA Hoechst Japan Ltd., Japan  
SO Eur. Pat. Appl., 19 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1



AB Title compds. I [R1,R2,R4 = alkyl, aryl, aralkyl (which groups may have  $\geq 1$  substituents); R3 = H, halo, alkyl, aryl, aralkyl (which groups may have  $\geq 1$  substituents)], useful as hypotensives and vasodilators (no data), are prepared by cyclocondensation of imidazoles II [R5 H, alkyl, aryl, aralkyl which groups may have  $\geq 1$  substituents)] with a thionyl halide in the presence of a tertiary amine, and optionally reacting the resulting product with a halogenating agent. A mixture of hexylthiobromine and 3N NaOH was refluxed for 6 h to give 38% II (R2 = hexyl; R2 = R4 = Me; R5 = H), to which SOCl<sub>2</sub> in pyridine was added and the mixture was stirred at ambient temperature for 3 h to afford 64% I (R1 = R4 =

Me, R2 = hexyl, R3 = H).


IT 119229-81-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of imidazothiadiazine hypotensives and vasodilators)

RN 119229-81-1 CAPLUS

CN 1H-Imidazole-5-carboxamide, N-phenyl-4-(phenylamino)-2-(phenylmethyl)-1-propyl- (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:38935 CAPLUS

DN 110:38935

TI Reactions of mesoionic five-membered heterocycles with o-quinoid compounds. VII. Thermal [ $\pi 4 + \pi 4$ ]cycloadditions of a bicyclic imidazolo[1,2-c]thiazole system

AU Friedrichsen, Willy; Koenig, B. Michael; Debaerdemaeker, Tony

CS Inst. Org. Chem., Univ. Kiel, Kiel, D-2300, Fed. Rep. Ger.

SO Zeitschrift fuer Naturforschung, B: Chemical Sciences (1988), 43(3), 347-60

CODEN: ZNBSEN; ISSN: 0932-0776



DT Journal

LA German

OS CASREACT 110:38935

GI






AB 5-(4-Methylphenyl)-2,7-diphenyl-4-phenylcarbamoylimidazolo[1,2-c]thiazole reacts with tetrachloro-o-benzoquinone to give a  $[\pi 4 + \pi 4]$ cycloadduct (I). In an obviously analogous manner 5-(4-methylphenyl)-2,7-diphenylimidazolo[1,2-c]thiazole reacts with N,N'-benzenesulfonyl-o-benzoquinonediimine to give adduct II. I solvolyzes with alcs. in a stereoselective  $SN_2''$  reaction giving imidazothiazoles III (R = Me, CHMe<sub>2</sub>). The stereochem. outcome of this reaction has been determined by an x-ray anal. of III (R = Me).

IT 117034-92-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and hydrolysis of)

RN 117034-92-1 CAPLUS

CN 1H-Imidazole-4-carboxamide, 2-benzoyl-5-(4-methylphenyl)-N-phenyl- (9CI)  
 (CA INDEX NAME)



L6 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1983:405563 CAPLUS

DN 99:5563

TI Nitroimidazoles: Part XVII. 5-Aminoimidazoles

AU Sudarsanam, V.; Nagarajan, K.; Gokhale, N. G.

CS Ciba-Geigy Res. Cent., Bombay, 400 063, India


SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1982), 21B(12), 1087-91  
 CODEN: IJSBDB; ISSN: 0376-4699

DT Journal


LA English

OS CASREACT 99:5563


GI




I



II



III



IV


AB 2-Benzoyl-1-methyl-5-nitroimidazole I (R = H) undergoes reduction over Raney nickel catalyst to the amine, which is transformed into II (R1 = p-ClC6H4CO, EtO2CNHCS, p-MeC6H4SO3NHCS, PhCONHCS). Hydrogenation of the I (R = NO2) and condensation of the product with DMF dimethyl acetal leads to a bis-amidine. Catalytic reduction of the nitrosulfone III (R2 = NO2) affords unstable III (R2 = NH2) which was converted into stable N-acyl derivs. and thioureas. Reaction of III (R2 = NH2) with p-O2NC6H4CHO furnishes in low yield an anomalous product considered to be IV which probably results via the benzylidene-bisimidazole and the tricyclic condensed pyridines. 2-Methylsulfonyl-1-methyl-5-aminoimidazole arising from the nitro derivative is characterized as the acylthioureas. Likewise the reduction product of 1-methylsulfonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone was isolated as the acetyl amino derivative

IT 86008-39-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 86008-39-1 CAPLUS

CN Benzamide, N-(2-benzoyl-1-methyl-1H-imidazol-5-yl)-4-chloro- (9CI) (CA  
INDEX NAME)



L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:515750 CAPLUS

DN 81:115750

TI Systemic and chemotherapeutic fungicidal activity-chemical structure  
relation of some 4-methyl-5-thiazolecarboxylic acid derivatives.  
Laboratory screening tests

AU Abdel-Lateef, Mahmoud F. A.; Stec, Maria; Eckstein, Zygmunt

CS Fac. Agric., Al-Azhar Univ., Cairo, Egypt

SO Acta Phytopathologica Academiae Scientiarum Hungaricae (1973), 8(3-4),  
269-82

CODEN: APYPBZ; ISSN: 0001-6780

DT Journal


LA English

AB Of 137 synthetic 4-methyl-5-thiazolecarboxylates (I, X = H, halo, Me, SH, alkoxy, aryloxy, alkylthio, arylthio, aryloxyalkyl heterocyclic radical, etc. R = HO, alkoxy, substituted amine, etc) 108 were previously undescribed. I compds. were screened with *Alternaria tenuis*, *Phytophthora infestans*, *Rhizoctonia*, *solani*, *Tilletia caries*, and *Venturia inaequalis* for chemical structure-activity relations. The m.p., yield, and fungicidal activities of I compds. are tabulated, and their structure-activity relations are discussed.

IT 53040-09-8P 53040-10-1P  
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and fungicidal activity of)


RN 53040-09-8 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-N-phenyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 53040-10-1 CAPLUS

CN 5-Thiazolecarboxamide, 2-(diphenylmethyl)-4-methyl-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1973:147941 CAPLUS

DN 78:147941

TI Thiazole-5-carboxanilide hydrochlorides

IN Girgis, Mikhail Milad

PA Uniroyal Ltd.

SO Ger. Offen., 18 pp.  
 CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2242471	A1	19730308	DE 1972-2242471	19720829
	US 3794636	A	19740226	US 1971-177822	19710903
	CA 970779	A1	19750708	CA 1972-148093	19720727
	GB 1401680	A	19750730	GB 1972-40027	19720829
	FR 2152056	A5	19730420	FR 1972-31134	19720901
	NL 7211992	A	19730306	NL 1972-11992	19720902
	IT 968312	A	19740320	IT 1972-69805	19720902
	JP 48039477	A2	19730609	JP 1972-88608	19720904
PRAI	US 1971-177822	A	19710903		

GI For diagram(s), see printed CA Issue.  
 AB Eight title compds. (I, Rn = H, 2,4,6-Me3, or 2-MeO; R1 = Me, Pr, CH2Ph, or C6H4Me-o), useful as fungicides and plant growth regulators were prepared by reaction of R1CSNH2 MeCOCHClCO- NHC6H5-nRn in R1CN or MeCN. Thus, MeCSNH2 in MeCN reacted with MeCOCHClCONHPh for 20 min at 65-70° to give 95% I (Rn = H, R1 = Me).  
 IT 41470-23-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 41470-23-9 CAPLUS  
 CN 5-Thiazolecarboxamide, 4-methyl-N-phenyl-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1963:53202 CAPLUS  
 DN 58:53202  
 OREF 58:9040e-h  
 TI Compounds with potential antitubercular activity. IV. N-Substituted thioamides of 4-Oxazolecarboxylic acids  
 AU Sycheva, T. P.; Trupp, T. Kh.; Shchukina, M. N.  
 CS S. Ordzhonikidze All-Union Chem.-Pharm. Research Inst., Moscow  
 SO Zhurnal Obshchei Khimii (1962), 32, 2882-5  
 CODEN: ZOKHAA; ISSN: 0044-460X  
 DT Journal  
 LA Unavailable  
 GI For diagram(s), see printed CA Issue.  
 AB cf. CA 58, 1448h. Addition of 6.9 g. POCl3 to 3.81 g. 2-methyl-4-oxazolecarboxylic acid and 2.79 g. PhNH2 and heating 1 hr. at 130° gave after an aqueous treatment 8.9 g. 2-methyl-4-oxazolecarboxanilide (I, R = Me) (II), m. 133.5-5.5°. Similarly were prepared the following I (R given): PhCH2, m. 109.5-11°; Ph, m. 187-9°; p-MeC6H4, m. 180.5-2.5°. Similarly were prepared: 2-benzyl-4-oxazolecarbomoypholide, m. 108-10° and the corresponding p-toluidide, m. 121-2°. II (1 g.) in 25 ml. pyridine heated with 2 g. P2S5 at 120-30° (bath temperature) 4 hrs. gave after an aqueous treatment and extraction of the precipitate with hot MeOH, 0.25 g. yellow 2-methyl-4-oxazolecarbothioanilide (III), m. 123-5°. Similarly were prepared the III analogs with following 2-substituents: PhCH2, m. 111-13.5; Ph, m. 104-5°. Similarly were prepared 2-benzyl-4-oxazolecarbothio-p-toluidide, m. 91-3°, and the analogous thiomorpholide, m. 94-6°. 2-p-Tolyl-4-oxazolecarboxanilide and P2S5 in pyridine 10 hrs. at 120-30° gave after an aqueous treatment yellow 2-p-tolyl-4-thiazolecarbothioanilide, m. 147-9°. Et 2-p-tolyl-4-oxazolecarboxylate in 2N NaOH 1 hr. gave the free acid, decomposed 229-30°. The replacement of the hetero O atom by S in the reaction with P2S5 was not observed for the other examples above.  
 IT 93323-65-0, 4-Oxazolecarboxanilide, 2-benzyl- 98511-88-7  
 , 4-Oxazolecarboxy-p-toluidide, 2-benzyl-

(preparation of)


RN 93323-65-0 CAPLUS

CN 4-Oxazolecarboxanilide, 2-benzyl- (7CI) (CA INDEX NAME)




RN 98511-88-7 CAPLUS

CN 4-Oxazolecarboxy-p-toluidide, 2-benzyl- (7CI) (CA INDEX NAME)



AN 2005:471944 CAPLUS  
 DN 143:26594  
 TI Preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette (ABC) transporters  
 IN Hadida Ruah, Sarah S.; Miller, Mark T.; Grootenhuis, Peter D. J.; Hamilton, Matthew  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 146 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005049018	A1	20050602	WO 2004-US38566	20041115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005130970	A1	20050616	US 2004-989218	20041115
PRAI	US 2003-520355P	P	20031114		
OS	MARPAT 143:26594				
GI					



AB A method of modulating ABC transporter activity comprises administration of title compds. [I; X = O, S; R1 = H, 3-8 membered (substituted) (unsatd.) (heterocyclic) ring; Z = bond, (substituted) (heteroatom-interrupted) alkylidene; R2 = halo, CF3, cyano, NO2, TqR; R3 = UmR'; R4 = VpCyl; m, p, q = 0, 1; U, V, T = (substituted) (heteroatom-interrupted) alkylidene; Cyl = 3-8 membered (substituted) (unsatd.) (heterocyclic) ring; R = H, (substituted) aliphatic; R' = R, (substituted) (unsatd.) (heterocyclic) ring]. Thus, 2-(4-methoxybenzyl)thiazole-4-carboxylic acid, C-[1-(3,4-dimethoxyphenyl)cyclopentyl]methylamine (preparation given), Et3N, and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate were stirred together for 16 h in MeCN to give 43.9% 2-(4-methoxybenzyl)thiazole-4-carboxylic acid [1-(3,4-dimethoxyphenyl)cyclopentyl]methylamide. Some I exhibit a relative modulating efficacy of >30%.


IT 852639-06-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters)

RN 852639-06-6 CAPLUS  
CN 4-Thiazolecarboxamide, 2-[(2,6-dichlorophenyl)methyl]-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l15  
 L15 HAS NO ANSWERS  
 L15 STR



VAR G1=O/S/N  
 VAR G2=1/5  
 VAR G3=32/35/38  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 42

STEREO ATTRIBUTES: NONE

=> s l15 ful  
 FULL SEARCH INITIATED 13:14:45 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 65921 TO ITERATE

100.0% PROCESSED 65921 ITERATIONS  
 SEARCH TIME: 00.00.02

73 ANSWERS

L16 73 SEA SSS FUL L15

=> fil caplus  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
167.38	490.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
 CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-12.00

FILE 'CAPLUS' ENTERED AT 13:14:50 ON 25 MAY 2006



USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2006 VOL 144 ISS 22  
FILE LAST UPDATED: 24 May 2006 (20060524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l16

L17 12 L16

=> s l17 not l5

L18 10 L17 NOT L5

=> d bib abs hitstr 1-10

L18 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:735380 CAPLUS

DN 143:211902

TI Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors

IN Chen, Bang-Chi; Zhao, Rulin; Wang, Bei

PA USA

SO U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2005176965	A1	20050811	US 2005-49815	20050203
	WO 2005076990	A2	20050825	WO 2005-US3807	20050204
	WO 2005076990	A3	20051124		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2004-542465P	P	20040206		
	US 2005-49815	A	20050203		
OS	MARPAT 143:211902				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention is directed to processes for preparing 2-aminothiazole-5-carboxamides I [R1, R2 = H, alkyl, aryl, etc.; or R1 is taken together with R2, to form heteroaryl or heterocyclo; R3 = H, CN, haloalkyl, etc.; R4, R5 = H, alkyl, aryl, etc.; or R5 is taken together with R4, to form heteroaryl or heterocyclo] comprising reacting XCH2C(O)NR1R2 [R1, R2 as above; X = leaving group] with R4N(R5)C(S)N:C(R3)NR6R7 [R3-R5 as above; R6, R7 = alkyl, alkenyl, aryl, etc.; or R6 is taken together with R7, to form heteroaryl or heterocyclo]. Thus, reacting II with III (preparation of both reactants given) afforded (S)-IV. The exemplified compds. I have been tested and shown activity as kinase inhibitors, in particular, inhibitors of Src kinase, p38 $\alpha/\beta$  enzymes, and/or TNF- $\alpha$  (no data given). The pharmaceutical composition for treating a kinase associated condition comprising the compound I is disclosed.

IT 745076-70-4P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors)

RN 745076-70-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-[(2-chlorophenyl)amino]-N-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:1082034 CAPLUS

DN 142:56293

TI P-38 inhibitors

IN Dong, Qing; Pierre, Fabrice; Wang, Jianqiang

PA USA

SO U.S. Pat. Appl. Publ., 76 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004254236	A1	20041216	US 2004-860768	20040602
	AU 2004251668	A1	20050106	AU 2004-251668	20040602
	CA 2528438	AA	20050106	CA 2004-2528438	20040602
	WO 2005000298	A2	20050106	WO 2004-US17580	20040602
	WO 2005000298	A3	20050303		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1635824 A2 20060322 EP 2004-754233 20040602  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-475662P P 20030603  
 US 2003-531541P P 20031219  
 WO 2004-US17580 W 20040602

OS MARPAT 142:56293  
 GI



AB 5-Membered heterocycle-based p38 kinase inhibitors I (R1 = H, Me, halogen, OH, lower alkyl, lower cycloalkyl, lower alkynyl, CF3, OMe, OCF3, CN, NH2, alkylamine, alkoxy; R2 = alkyl, substituted alkyl, lower cycloalkyl, halo, CF3, OCF3, alkoxy, alkylamine, sulfoxy, sulfone, amide, and n = 0, 1, or 2; R3 = H, alkyl, alkoxy, substituted alkyl, cycloalkyl, heteroaryl, heterocycle; Y = a single bond, C(O)NH, NHC(O), NHC(O)NH, SO2NH, NHSO2, C(O); B = a 5-membered heterocyclic ring system optionally substituted; Q = a single bond, O, S, alkylamine, SO, SO2, C(O), CO(O), C(O)NH, CH2; D = a monocyclic or bicyclic ring system) are prepared for the treatment of inflammatory and autoimmune diseases. Thus, to 3-amino-N-methoxy-4-methylbenzamide in CH2Cl2 was added benzoyl isothiocyanate, and N, N-diisopropylethylamine followed by treatment with hydrazine monohydrate to give II. II had an IC50 of less than 50 nM against p38α.


IT 808737-95-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of p-38 kinase inhibitors for the treatment of inflammatory and autoimmune diseases)


RN 808737-95-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




L18 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:878168 CAPLUS  
 DN 141:360665  
 TI Synergistic methods and compositions using insulin-like growth factor 1  
 receptor (IGF1R) inhibitors with additional kinase inhibitors for treating  
 cancer  
 IN Carboni, Joan M.; Hurlburt, Warren W.; Gottardis, Marco M.; Lee, Francis  
 Y.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 676,214.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209930	A1	20041021	US 2004-814199	20040331
	CA 2500714	AA	20040415	CA 2003-2500714	20031001
	US 2004072760	A1	20040415	US 2003-677067	20031001
	AU 2003275364	A1	20040423	AU 2003-275364	20031001
	US 2004106605	A1	20040603	US 2003-676214	20031001
	EP 1551411	A2	20050713	EP 2003-759640	20031001
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006503867	T2	20060202	JP 2004-541997	20031001
	WO 2005094376	A2	20051013	WO 2005-US10820	20050330
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-415416P	P	20021002		
	US 2003-676214	A2	20031001		
	US 2003-677067	A2	20031001		
	WO 2003-US31091	W	20031001		
	US 2004-814199	A	20040331		
OS	MARPAT 141:360665				
AB	Combination therapies using IGF1R inhibitors in combination with addnl. kinase inhibitors are described for the synergistic treatment of cancer.				
IT	302963-66-2 302963-70-8 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (IGF1 receptor inhibitors with addnl. kinase inhibitors for synergistic treatment of cancer)				
RN	302963-66-2 CAPLUS				
CN	5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[5-[[3-(1H-imidazol- 1-yl)propyl]amino]-2-nitrophenyl]amino]- (9CI) (CA INDEX NAME)				



RN 302963-70-8 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-methoxyphenyl)amino]-(9CI) (CA INDEX NAME)



L18 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:701968 CAPLUS

DN 141:225499

TI Preparation of thiazolyl amide derivatives as p38 kinase inhibitors

IN Hynes, John; Wu, Hong; Leftheris, Katerina; Liu, Chunjian; Das, Jagabandhu; Moquin, Robert V.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004071440	A2	20040826	WO 2004-US3879	20040206
	WO 2004071440	A3	20041209		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,			



LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,  
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,  
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG

US 2004220233 A1 20041104 US 2004-773790 20040206  
 EP 1594854 A2 20051116 EP 2004-709122 20040206

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRAI US 2003-445410P P 20030206  
 WO 2004-US3879 W 20040206

OS MARPAT 141:225499  
 GI



AB Title compds. represented by the formula I [wherein A = Ph or pyridinyl; X = hydroxy, (un)substituted alkoxy, (alkylene)amino, amido, etc.; Y = CONR1 or NR1CO; R1 = H, (un)substituted cycloalkyl(alkyl), (hetero)aryl(alkyl), (heterocyclo)alkyl; R2 = H, alkyl, (hetero)cycloalkyl(alkyl), (hetero)aryl(alkyl); R3 = H, (halo)alkyl, alkoxy(alkyl), etc.; B = H, hydroxy, heterocycle, etc.; Z1 = (un)substituted alkyl, alkenyl, cyano, etc.; m = 0-3; n = 0-1; and enantiomers, diastereomers, pharmaceutically acceptable salts or solvates thereof] were prepared as kinase inhibitors (no data). For example, II was prepared in a multiple-step synthesis starting from Me 2-amino-5-thiazolylcarboxylate. Thus, I and their pharmaceutical compns. are useful for the treatment of p38 kinase-associated conditions (no data).


IT 745076-70-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazolyl-5-amide derivs. as p38 kinase inhibitors)

RN 745076-70-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-[(2-chlorophenyl)amino]-N-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:220082 CAPLUS

DN 140:253556

TI Preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors

IN Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Dowsyko, Arthur M. P.; Barrish, Joel C.; Wityak, John; Lombardo, Louis J.; Lee, Francis Y. F.

PA USA

SO U.S. Pat. Appl. Publ., 184 pp., Cont.-in-part of U.S. 6,596,746.

CODEN: USXXCO

DT Patent



LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004054186	A1	20040318	US 2003-395503	20030324
	US 6596746	B1	20030722	US 2000-548929	20000413
	US 2004024208	A1	20040205	US 2003-378372	20030303
	US 6979694	B2	20051227		
	US 2004073026	A1	20040415	US 2003-378461	20030303
	US 2004077875	A1	20040422	US 2003-378373	20030303
	AU 2004223828	A1	20041007	AU 2004-223828	20040323
	CA 2519898	AA	20041007	CA 2004-2519898	20040323
	WO 2004085388	A2	20041007	WO 2004-US8827	20040323
	WO 2004085388	A3	20050630		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1610780	A2	20060104	EP 2004-758053	20040323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008782	A	20060328	BR 2004-8782	20040323
	CN 1764454	A	20060426	CN 2004-80007845	20040323
	US 2005261305	A1	20051124	US 2005-138793	20050525
	US 2005288303	A1	20051229	US 2005-138942	20050526
	NO 2005004359	A	20051019	NO 2005-4359	20050920
	US 2006079563	A1	20060413	US 2005-271626	20051110
PRAI	US 1999-129510P	P	19990415		
	US 2000-548929	A2	20000413		

US 2003-378373	A1	20030303
US 2003-395503	A	20030324
WO 2004-US8827	W	20040323
MARPAT 140:253556		

OS  
GI



AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day. The pharmaceutical composition comprising the title compds. is claimed.

IT 302963-66-2P 302963-70-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

RN 302963-66-2 CAPLUS


CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[5-[[3-(1H-imidazol-1-yl)propyl]amino]-2-nitrophenyl]amino]- (9CI) (CA INDEX NAME)





RN 302963-70-8 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-methoxyphenyl)amino] - (9CI) (CA INDEX NAME)




IT 302964-14-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)


RN 302964-14-3 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(5-fluoro-2-nitrophenyl)amino] - (9CI) (CA INDEX NAME)




L18 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:571107 CAPLUS  
 DN 139:133557  
 TI Preparation of phenylimino thiazolylydene thiazolidinones and other  
 heterocyclic modulators of nuclear receptors with therapeutic uses  
 IN Martin, Richard; Flatt, Brenton Todd; Wang, Tie-Lin; Kahl, Jeffery Dean  
 PA X-Ceptor Therapeutics, Inc., USA  
 SO PCT Int. Appl., 481 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003060078	A2	20030724	WO 2002-US41224	20021220
	WO 2003060078	C2	20040219		
	WO 2003060078	C1	20040429		
	WO 2003060078	A3	20040624		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002367060	A1	20030730	AU 2002-367060	20021220
	US 2003212111	A1	20031113	US 2002-329668	20021220
	US 6696473	B2	20040224		
	EP 1465882	A2	20041013	EP 2002-806505	20021220
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	US 2004180942	A1	20040916	US 2003-717049	20031118
PRAI	US 2001-342720P	P	20011221		
	US 2002-329668	A1	20021220		
	WO 2002-US41224	W	20021220		
OS	MARPAT 139:133557				
GI					



I



II


AB Phenylimino thiazolylidene thiazolidinones and other heterocyclic compds. (shown as I or its E/Z isomer; variables defined below; e.g. 3-benzyl-5-(3-methyl-3H-benzothiazol-2-ylidene)-2-thioxothiazolidin-4-one (shown as II)), compns. and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compds. are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. FXR agonism properties of >200 examples of I are tabulated. For I, X1, X2 and X3 = (i) or (ii) as follows: (i) X1, X2 and X3 = S, O or NR5; or (ii) X1 is -CR8:CR9- (R8 and R9 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.) and X2 and X3 = S, O or NR5. R1 is (un)substituted alkyl; R2 is (un)substituted aralkyl, aryl, alkenyl, alkyl, cycloalkyl, heteroaralkyl, or heterocyclalkyl; R3 is (un)substituted heteroaryl, aryl, or aralkyl. A and G = (i), (ii) or (iii) as follows: (i) A and G = H, (un)substituted aryl, (un)substituted alkyl, (un)substituted alkoxycarbonyl, hydroxycarbonyl, and (un)substituted alkylcarbonyl; or (ii) A and G together form (un)substituted alkylene or azaalkylene; or (iii) A and G together form substituted butadienyl; D and E are each H, or together form a bond; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, .apprx.290 example preps. are included.

IT 562825-59-6P, 3-[[3-Benzyl-5-(1,3-dimethyl-1,3-dihydrobenzimidazol-2-ylidene)-4-oxothiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylimino thiazolylidene thiazolidinones and other heterocyclic modulators of nuclear receptors with therapeutic uses)


RN 562825-59-6 CAPLUS

CN Benzonitrile, 3-[[5-(1,3-dihydro-1,3-dimethyl-2H-benzimidazol-2-ylidene)-4-oxo-3-(phenylmethyl)-2-thiazolidinylidene]amino]-4-(ethylamino)- (9CI)  
 (CA INDEX NAME)




TI Preparation of aminocarbonyl-heterocyclic imines and their uses as agrochemical fungicides and insecticides  
 IN Niki, Toshio; Kikuchi, Takamasa; Kudo, Takao; Suzuki, Hiroyuki; Hayasaka, Fumio  
 PA Nissan Chemical Industries, Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 89 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1  

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 2003081951	A2	20030319	JP 2002-184841	20020625
PRAI	JP 2001-193575	A	20010626		
OS	MARPAT 138:238167				
GI					





AB Title compds. I [A = (un)substituted hetero ring residue; X = halo, C1-6 (halo)alkyl, NO<sub>2</sub>, CN, CHO, etc.; n = 0-4; G = CH<sub>2</sub>CO<sub>2</sub>Me, etc.] and/or their agriculturally acceptable salts are prepared Thus, condensation of aniline with 2-(2-methoxycarbonylmethylphenylimino)-[1,3]oxathiol-5-carboxylic acid in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl salt in pyridine gave Me [2-(5-phenylcarbamoyl-[1,3]oxathiol-2-ylideneamino)phenyl]acetate, which showed ≥70% antifungal activity against Erysiphe graminis.  
 IT 501921-12-6P  
 RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heterocyclic imines as agrochem. fungicides and insecticides)  
 RN 501921-12-6 CAPLUS  
 CN Benzeneacetic acid, 2-[[3-methyl-4-[(phenylamino)carbonyl]-2(3H)-thiazolylidene]amino]-, methyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2000:756524 CAPLUS  
 DN 133:321878  
 TI Preparation of cyclic protein tyrosine kinase inhibitors  
 IN Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Dowsyko, Arthur M. P.; Barrish, Joel C.; Wityak, John  
 PA Bristol-Myers Squibb Co., USA  
 SO PCT Int. Appl., 300 pp.

CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000062778	A1	20001026	WO 2000-US9753	20000412
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2366932	AA	20001026	CA 2000-2366932	20000412
	AU 2000042338	A5	20001102	AU 2000-42338	20000412
	AU 779089	B2	20050106		
	EP 1169038	A1	20020109	EP 2000-922102	20000412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009721	A	20020213	BR 2000-9721	20000412
	TR 200102969	T2	20020821	TR 2001-200102969	20000412
	JP 2002542193	T2	20021210	JP 2000-611914	20000412
	NZ 513639	A	20040227	NZ 2000-513639	20000412
	RU 2260592	C2	20050920	RU 2001-130452	20000412
	ZA 2001007204	A	20021202	ZA 2001-7204	20010830
	NO 2001004970	A	20011210	NO 2001-4970	20011012
	US 2005261305	A1	20051124	US 2005-138793	20050525
	US 2005288303	A1	20051229	US 2005-138942	20050526
	US 2006079563	A1	20060413	US 2005-271626	20051110
PRAI	US 1999-129510P	P	19990415		
	WO 2000-US9753	W	20000412		
	US 2000-548929	A1	20000413		
	US 2003-378373	A1	20030303		
OS	MARPAT 133:321878				
GI					



AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together


= O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day.

IT 302963-66-2P 302963-70-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of cyclic protein tyrosine kinase inhibitors)


RN 302963-66-2 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[5-[[3-(1H-imidazol-1-yl)propyl]amino]-2-nitrophenyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-70-8 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)




IT 302964-14-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of cyclic protein tyrosine kinase inhibitors)

RN 302964-14-3 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(5-fluoro-2-nitrophenyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:440935 CAPLUS

DN 127:61966

TI Synthesis of new 2-iminothiazolines and their antifungal activities

AU Hahn, Hoh-Gyu; Nam, Kee Dal; Kim, Byung Sup; Cho, Kwang Yun

CS Organic Chemistry Lab., Korea Inst. Science and Technology, Seoul, 136-791, S. Korea

SO Han'guk Nonghwa Hakhoechi (1997), 40(2), 139-143

CODEN: JKACA7; ISSN: 0368-2897

PB Korean Society of Agricultural Chemistry and Biotechnology

DT Journal

LA Korean

AB New 2-iminothiazoline derivs. were prepared and tested for their biol. activity. For preparation of 2-iminothiazolines, primary amines were reacted with isothiocyanate, then with  $\alpha$ -halo ketone derivs. Their antifungal activity was tested against six different plant diseases. A compound that has a phenylimino group at C-2, Me at C-3, phenylcarbamoylmethyl at C-4, and hydrogen at C-5 on the thiazoline skeleton was found to be most active.

IT 191466-62-3P 191466-63-4P 191466-64-5P

191466-65-6P 191466-66-7P 191466-67-8P

191466-68-9P 191466-69-0P 191466-70-3P

191466-71-4P 191466-72-5P 191466-75-8P


191466-76-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of 2-iminothiazolines and their antifungal activities)


RN 191466-62-3 CAPLUS

CN 5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3,4-dimethyl-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 191466-63-4 CAPLUS  
 CN 5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3-methyl-N,4-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-64-5 CAPLUS  
 CN 5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-N-(4-fluorophenyl)-2,3-dihydro-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 191466-65-6 CAPLUS  
 CN 5-Thiazolecarboxamide, N-(2,6-dichlorophenyl)-2-[(2,4-




dimethylphenyl) imino]-2,3-dihydro-3,4-dimethyl-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 191466-66-7 CAPLUS  
CN 5-Thiazolecarboxamide, N-(2,5-dichlorophenyl)-2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3,4-dimethyl-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 191466-67-8 CAPLUS  
CN 5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-N-(2-methoxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 191466-68-9 CAPLUS  
 CN 5-Thiazolecarboxamide, N-(4-cyanophenyl)-2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 191466-69-0 CAPLUS  
 CN 5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3,4-dimethyl-N-(4-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 191466-70-3 CAPLUS  
 CN 5-Thiazolecarboxamide, 2-[(4-chloro-2-methylphenyl)imino]-2,3-dihydro-3,4-dimethyl-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 191466-71-4 CAPLUS  
 CN 5-Thiazolecarboxamide, 2-[(4-chloro-2-methylphenyl)imino]-2,3-dihydro-3-methyl-N,4-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-72-5 CAPLUS  
 CN 5-Thiazolecarboxamide, 2-[(4-chloro-2-methylphenyl)imino]-N-(4-


chlorophenyl)-2,3-dihydro-3,4-dimethyl-, monohydrochloride (9CI) (CA  
INDEX NAME)



● HCl

RN 191466-75-8 CAPLUS


CN 4-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3,5-dimethyl-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-76-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-[(4-chloro-2-methylphenyl)imino]-2,3-dihydro-3,5-dimethyl-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

AN 1967:65472 CAPLUS  
 DN 66:65472  
 TI 2-(2-Substituted-4-thiazolyl)benzimidazole derivatives  
 IN Tashika, Yoshio; Takanashi, Kumiko  
 SO Jpn. Tokkyo Koho, 3 pp.  
 CODEN: JAXXAD  
 DT Patent  
 LA Japanese  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 41020220	B4	19631125	JP	19631129

GI For diagram(s), see printed CA Issue.  
 AB Manufacture of I (R1 at C-5 or C-6), useful as anthelmintic and insecticides, is described. In an example, 2.9 g. 5(or 6)-nitro-2-( $\alpha$ -oxobromoethyl)benzimidazole and 1.9 g. p-chlorophenylthiourea are dissolved in 50 cc. 2-ethoxyethanol, the whole refluxed 5-6 hrs., evaporated, H<sub>2</sub>O added to the residue, the mixture made alkaline with NH<sub>4</sub>OH, and the precipitated mass recrystd. from 50% EtOH to give 64% I (R1 = 5(or 6)-NO<sub>2</sub>, R2 = p-chloroanilino), m. 266°. Similarly prepared are the following I (R1 R2, and m.p. given): H, H, >300°; NO<sub>2</sub>, H, >300°; H, NH<sub>2</sub>, 261°; H, PhNH, 129.5-30°; Cl, NH<sub>2</sub>, 234-6°; Cl, NHMe, 274-6°; Cl, NHEt, 228.5-29°; Cl, NHPh, 129°; Cl, p-chloroanilino, 150-4°; Cl, p-bromoanilino, 268°; Cl, o-methoxyanilino, 283°; Cl, m-nitroanilino, 175-6°; NO<sub>2</sub>, NH<sub>2</sub>, >300°; NO<sub>2</sub>, NHMe, >300°; NO<sub>2</sub>, NHPh, 267°; NO<sub>2</sub>, m-nitroanilino, 206°; H, Me, 168-9°; Cl, Me, 169-70°; Me, Me, 270-2°.

IT 14521-72-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 14521-72-3 CAPLUS  
 CN Benzimidazole, 2-(2-o-anisidino-4-thiazolyl)-5-chloro- (8CI) (CA INDEX NAME)



```
=> d l1
L1 HAS NO ANSWERS
L1 STR
```



```
VAR G1=C/N
VAR G2=X/C/N/O
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 8
```

```
STEREO ATTRIBUTES: NONE
```


```
=> d l11
L11 HAS NO ANSWERS
L11 SCR 1839
```

```
=> d his l15
```

```
(FILE 'REGISTRY' ENTERED AT 12:27:32 ON 25 MAY 2006)
L15 7961 S L1 NOT L11 FUL
```


```
=> save l15
ENTER NAME OR (END):10775980/a
10775980/A IS NOT A VALID SAVED NAME
Enter the name you wish to use for the saved query,
answer set, or L-number list. The name must:
1. Begin with a letter,
2. Have 1-12 characters,
3. Contain only letters (A-Z) and numbers (0-9),
4. End with /Q for a query (search profile,
structure, or screen set), /A for an answer
set, or /L for an L-number list.
5. Not already be in use as a saved name,
6. Not be END, SAV, SAVE, SAVED
7. Not have the form of an L-number (Lnnn).
ENTER NAME OR (END):sm775980/a
ANSWER SET L15 HAS BEEN SAVED AS 'SM775980/A'
```

IN 1,2,4-Triazin-3(2H)-one, 6-amino-5-(dimethylamino)- (9CI)  
MF C5 H9 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L16 108 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Hydrazinecarboxylic acid, 2-(6-amino-3-methyl-1,2,4-triazin-5-yl)-,  
ethyl ester (9CI)  
MF C7 H12 N6 O2





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*



L16 108 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1,2,4-Triazine-6-carboxylic acid, 5-amino-, ethyl ester (9CI)  
MF C6 H8 N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


Scheme 7Scheme 8

5


Scheme 9

10





Scheme 10



Scheme 11

